Sarepta Therapeutics Inc
(LTS:0L35)
$
121.67
0 (0%)
Market Cap: 11.61 Bil
Enterprise Value: 11.80 Bil
PE Ratio: 78.90
PB Ratio: 9.50
GF Score: 82/100 Sarepta Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 18, 2021 / 06:30PM GMT
Release Date Price:
$83.54
(+11.11%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Hi, good afternoon everyone. I'm Brian Abrahams, Senior Biotech Analyst at RBC Capital Markets. I'm really pleased to have with us our next presenting company, Sarepta Therapeutics, represented by their CFO, Ian Estepan. Ian, thanks for joining us.
Ian Michael Estepan
Sarepta Therapeutics, Inc. - Executive VP & CFO
Thank so much. Doug should be on his way. It seems like he's having technical difficulties, but I'm sure he'll figure it out in a little bit.
Questions & Answers
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Well, let's get started in the meantime because, obviously, a lot to cover on what's been a very exciting day. So I guess, first off, congratulations on the Study 103 results you shared this morning. What have you learned from the -- overall from the performance of the scaled up material in terms of similarity of the product to the clinical-grade
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot